Show simple item record

dc.contributor.authorMcMillin, Douglas William
dc.contributor.authorMitsiades, Constantine S
dc.date.accessioned2013-04-24T19:37:09Z
dc.date.issued2012
dc.identifier.citationMcMillin, Douglas William, and Constantine S. Mitsiades. 2012. High-throughput approaches to discover novel immunomodulatory agents for cancer. Oncoimmunology 1(8): 1406-1408.en_US
dc.identifier.issn2162-4011en_US
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:10581973
dc.description.abstractThe clinical success of immunomodulatory thalidomide derivatives has renewed the general interest in immunomodulatory anticancer compounds and prompted us to develop a high-throughput system to quantify immune effector-cell activity. We documented that the interaction between cancer cells, their stroma, anticancer agents and cells from the innate system are critical for determining the response of tumors to immunomodulatory strategies.en_US
dc.language.isoen_USen_US
dc.publisherLandes Bioscienceen_US
dc.relation.isversionofdoi:10.4161/onci.21058en_US
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518518/pdf/en_US
dash.licenseLAA
dc.subjectcanceren_US
dc.subjecthigh-throughput screeningen_US
dc.subjectimmune effector cellsen_US
dc.subjectpharmacological immunomodulatorsen_US
dc.subjecttumor heterogeneityen_US
dc.titleHigh-throughput approaches to discover novel immunomodulatory agents for canceren_US
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden_US
dc.relation.journalOncoimmunologyen_US
dash.depositing.authorMitsiades, Constantine S
dc.date.available2013-04-24T19:37:09Z
dc.identifier.doi10.4161/onci.21058*
dash.contributor.affiliatedMcMillin, Douglas
dash.contributor.affiliatedMitsiades, Constantine


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record